Introgen Therapeutics Inc. has applied to the U.S. Food and Drug Administration (FDA) for priority review of Advexin p53 for the treatment of recurrent head and neck cancer.
Advexin combines the p53 tumor suppressor with a non-replicating, non-integrating adenoviral delivery system.
Application for priority review is based on results from Phase II and Phase III trials evaluating Advexin in the treatment of recurrent, end-stage, squamous-cell head and neck cancer.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
